Welcome to our dedicated page for Esperion Therapeutics SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Esperion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Esperion Therapeutics's regulatory disclosures and financial reporting.
Esperion Therapeutics, Inc. is offering additional shares of its common stock on a shelf registration, with the final public offering price to be set at pricing. The company reported a closing Nasdaq price of $3.30 per share on October 3, 2025 and had 202,149,464 shares outstanding as of June 30, 2025. The prospectus details intended uses of proceeds for commercialization of NEXLETOL and NEXLIZET, pipeline development, working capital and general corporate purposes. Recent corporate developments include a settlement with Dr. Reddy’s delaying generic entry in the U.S. until April 19, 2040 under specified conditions. The company reported a pro forma net tangible book deficit of approximately $(433.5) million (about $(2.14) per share) as of June 30, 2025, and discloses material dilution and volatility risks for investors.
Esperion Therapeutics, Inc. filed a current report to note that on October 7, 2025 it posted an updated corporate presentation on its investor relations website. The same presentation, dated October 2025, is also provided as Exhibit 99.1 so investors can review the materials directly through the SEC system.
The filing does not introduce new financial statements or disclose specific transaction details. Instead, it formally records that the latest corporate overview and investor slide deck are now publicly available, helping ensure all market participants have equal access to the company’s updated messaging.
Esperion Therapeutics insider transaction: Benjamin Looker, listed as General Counsel and an officer, reported a sale of 6,267 shares of Esperion Therapeutics common stock on 09/17/2025 at a reported price of $2.804 per share. The filing states the shares were sold to satisfy tax obligations on vested restricted stock units. After the sale, Mr. Looker is reported to beneficially own 393,670 shares, held directly. The Form 4 was signed by a power of attorney on 09/18/2025. The report contains no other derivative transactions or additional explanatory disclosures.
Sheldon L. Koenig, President and CEO and Director of Esperion Therapeutics (ESPR), reported a sale and updated holdings. On 09/17/2025 he disposed of 28,427 shares of Esperion common stock at $2.788 per share to satisfy tax obligations on vested restricted stock units. After the reported disposition and recent ESPP purchases, Koenig beneficially owns 1,518,831 shares, which includes 5,770 shares acquired through the company's Employee Stock Purchase Plan. The Form 4 filing is signed 09/18/2025 and reflects that the reporting person is both an officer and a director.
Esperion Therapeutics CFO Benjamin Halladay reported a sale and recent employee-plan purchase on Form 4. On 09/17/2025 he disposed of 7,046 shares of Esperion common stock at a price of $2.808 per share to satisfy tax obligations tied to vested restricted stock units. Following the reported transactions, Mr. Halladay beneficially owns 474,862 shares, which the filing notes includes 7,446 shares recently acquired through Esperion's Employee Stock Purchase Plan. The filing was signed by power of attorney on 09/18/2025.
Esperion Therapeutics (ESPR) report of proposed sale under Rule 144: An individual plans to sell 28,427 common shares through Fidelity Brokerage Services on 09/17/2025, with an aggregate market value of $79,240.27. The shares were acquired on 09/15/2025 via restricted stock vesting and payment was for compensation. The filing lists 201,622,825 shares outstanding, so the proposed sale represents a very small fraction of total shares. The filer also reported a prior sale of 30,474 shares on 06/17/2025 generating $33,792.63. The filing includes the seller's representation regarding material nonpublic information.
Form 144 filed for ESPR insider Benjamin Halladay proposes to sell 7,046 shares of common stock on or about 09/17/2025. The shares were acquired on 09/15/2025 upon restricted stock vesting and are being sold as compensation. The filing lists an aggregate market value of $19,788.69 for the proposed sale versus 201,622,825 shares outstanding, indicating the sale is a very small fraction of the company. The filer previously sold 7,229 shares on 06/17/2025 for $8,329.25 and 11 shares on 07/17/2025 for $12.27. The signer certifies no undisclosed material adverse information.
Esperion Therapeutics (ESPR) Form 144 notice: The filer reports a proposed sale of 6,267 common shares with an aggregate market value of $17,575.80, to be sold through Fidelity Brokerage Services LLC on or about 09/17/2025 on the NASDAQ. The shares were acquired on 09/15/2025 by restricted stock vesting from the issuer and were paid as compensation. The filing also discloses sales by the same person in the prior three months: 6,422 shares sold on 06/17/2025 for $7,397.50 and 1,304 shares sold on 07/17/2025 for $1,469.35. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information.
Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report beneficial ownership of 9,954,975 shares of Esperion Therapeutics common stock, representing 5.0% of the class based on 198,199,462 shares outstanding. The shares are held by Two Seas Global (Master) Fund LP, for which Two Seas Capital acts as investment adviser and has sole voting and dispositive power; TSC GP and Mr. Toussi are identified through their general partner and managing member roles.
The filing states the position is held in the ordinary course of business and not to change or influence control of the issuer. The disclosure quantifies position size and control over voting and disposition rights without indicating an intent to seek corporate control.
Esperion Therapeutics has registered an additional 6,250,000 shares of its common stock for issuance under the company’s 2022 Stock Option and Incentive Plan, as amended, following stockholder approval of the plan amendment on May 29, 2025. The Registration Statement on Form S-8 incorporates prior Form S-8 registration statements for the same class of securities.
This filing enables the company to grant additional equity awards under its incentive plan; it is a routine corporate step to implement the expanded reserve and does not itself change outstanding shares until awards are issued and exercised.